Virax rises on launch of triple respiratory virus rapid test
03/11/2022 11:58
** Shares of biotech co Virax Biolabs VRAX.O jump as much
as ~27% to $2.13 before the bell
** VRAX introduces RSV-Influenza-COVID triple virus antigen
rapid test kit in markets accepting the CE mark, which is a
manufacturer's declaration that a test complies with European
norms urn:newsml:reuters.com:*:nPn1bv3kDa
** Co says test kits can be used at-home and in
point-of-care settings to identify infections related to three
respiratory conditions - respiratory syncytial virus (RSV),
influenza and COVID-19
** Test kits typically provide results in 15 minutes - VRAX
** As of last close, VRAX has fallen ~91% since market debut
in July 2022
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))